Headlines about Miragen Therapeutics (NASDAQ:MGEN) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Miragen Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 46.0937231569126 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s rankings:
Shares of MGEN traded down $0.37 during midday trading on Friday, hitting $6.50. 219,209 shares of the company’s stock traded hands, compared to its average volume of 380,594. Miragen Therapeutics has a 1 year low of $5.01 and a 1 year high of $15.91. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.26. The firm has a market cap of $196.12, a PE ratio of -4.71 and a beta of 1.33.
Miragen Therapeutics (NASDAQ:MGEN) last issued its quarterly earnings data on Wednesday, March 14th. The medical research company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. Miragen Therapeutics had a negative return on equity of 63.57% and a negative net margin of 662.30%. The firm had revenue of $1.19 million during the quarter, compared to analyst estimates of $1.22 million. research analysts forecast that Miragen Therapeutics will post -1.17 EPS for the current year.
A number of research firms have weighed in on MGEN. Oppenheimer began coverage on Miragen Therapeutics in a report on Friday, January 12th. They set an “outperform” rating and a $13.00 target price for the company. Wedbush restated an “outperform” rating and set a $19.00 target price on shares of Miragen Therapeutics in a report on Wednesday, March 28th. B. Riley began coverage on Miragen Therapeutics in a report on Friday, January 5th. They set a “buy” rating and a $15.50 target price for the company. Chardan Capital restated a “buy” rating on shares of Miragen Therapeutics in a report on Tuesday, January 16th. Finally, Cann began coverage on Miragen Therapeutics in a report on Friday, January 12th. They set an “outperform” rating and a $13.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $16.31.
In other Miragen Therapeutics news, insider Adam Scott Levy acquired 9,090 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was purchased at an average price of $5.50 per share, for a total transaction of $49,995.00. Following the acquisition, the insider now owns 10,540 shares in the company, valued at approximately $57,970. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bruce Booth acquired 545,454 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were acquired at an average price of $5.50 per share, with a total value of $2,999,997.00. The disclosure for this purchase can be found here. Corporate insiders own 44.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/miragen-therapeutics-mgen-getting-somewhat-favorable-press-coverage-analysis-shows.html.
About Miragen Therapeutics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.